Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary

May 8, 2025

NASDAQ US Health Care Pharmaceuticals earnings 53 min

Earnings Call Speaker Segments

Korin Franklin

executive
#1

Thanks, Crystal, and good afternoon to all of you. We appreciate you being with us today; participating on this call are Howard Robin, who serves as our President and Chief Executive Officer; Dr. Jonathan Zalevsky, our Chief Research and Development Officer; Dr. Brian Kotzin, our Chief Medical Officer; and Sandra Gardiner, our Chief Financial Officer; during this call, we anticipate delivering forward-looking statements about our business, including statements concerning the therapeutic potential of and future development plans for drug candidates and research programs, when clinical studies will begin and when clinical data for drug candidates will become available, the timing of and plans for upcoming clinical data presentations, the formation, future development plans, or success of our collaboration agreements, financial guidance, and certain other statements about the future of our business. Since forward-looking statements concern the future, they carry uncertainties and risks that are hard to predict, many of which lie beyond our control, or actual results may differ materially from these statements. Key risks and uncertainties appear in our Form 10-K filed on March 14, 2025, which can be found at sec.gov. We assume no obligation to update any of these forward-looking statements, whether because of new information, future developments, or otherwise. A webcast of this call will be accessible on the IR page of Nektar's website at nektar.com; having said that, I'd like to turn the call over to our President and CEO, Howard Robin. Howard?

Howard W Robin

executive
#2

Thank you, Corinne, and I appreciate everyone being here with us today. Through Q1 of 2025, our attention has been fixed on moving our immunology pipeline forward successfully — specifically on pushing rezpegaldesleukin, which we also call REZPEG, ahead across three distinct phase II trials, while also wrapping up the IND enabling work for NKTR-0165, the TNFR2 agonist antibody that leads our earlier stage programs. REZPEG represents a first-in-class T regulatory cell biologic treatment carrying wide potential across many immune disorders. As a novel immune modulator mechanism, REZPEG is set up to assist a substantial number of patients who struggle with chronic conditions. Come June, we intend to disclose our initial top-line findings from the 16-week induction phase of the 400-patient phase 2b trial called RESOLVE-AD, which is examining REZPEG among biologic naive individuals suffering moderate to severe atopic dermatitis. In a moment, I'll have JZ walk through the key data milestone ahead along with how the study was designed. What we're aiming for in this trial is to show efficacy and safety and to identify a dose worth carrying into phase three studies. This trial also includes a 36-week maintenance phase, during which patients get the identical dose they received in induction, though on either a four-week or a 12-week dosing schedule. Findings from that maintenance phase should arrive in early 2026. Atopic dermatitis presents a major opportunity given the substantial unmet need for fresh mechanisms to treat these individuals. Right now, 30 million adults in the U.S. live with atopic dermatitis, and 220 million adults have it worldwide. Roughly half of them suffer moderate to severe disease, meaning their eczema affects a large share of their body and may seriously compromise their overall quality of life. The National Eczema Association reports that adults dealing with atopic dermatitis face triple the likelihood of anxiety and depression, and this risk grows along with disease severity. Eczema may additionally trigger intense itching and inflammation, disrupt a patient's sleep, and produce body shame. At present, around 8% of those with moderate to severe disease receive a biologic, most often Dupixent; we understand that roughly half of such patients eventually either fail to gain benefit from treatment or turn refractory, and when treatment halts, their atopic dermatitis comes back. Our view is that this happens because the approved biologics succeed at controlling the disease's signs and symptoms, yet they fail to therapeutically target the underlying disease pathology in order to restore and heal the skin. Being a T regulatory cell therapy, REZPEG works differently — it regulates multiple immune pathways to tackle the overall disorder, and we think it might deliver a much-needed option beyond the IL-13 and IL-31-based therapies that are currently approved for these patients. Turning to our REZPEG AA phase 2b trial in alopecia areata, top-line results are due in December of this year. Those enrolled in this trial have severe to very severe alopecia areata. These individuals have lost a minimum of 50% of the hair on their scalp. Beyond that, this condition may also affect a person's eyebrows, eyelashes, and facial hair. In the U.S., roughly 7 million individuals suffer from alopecia areata, while 160 million are affected globally. A number of these individuals additionally suffer from other autoimmune conditions. Our trial involving 90 patients is assessing a treatment window of 36 weeks among alopecia areata sufferers versus those receiving placebo. After that, we'll assess patients following discontinuation of therapy to grasp REZPEG's potential for long-term remission. At present, JAK inhibitors are prescribed for alopecia, and it's known that once treatment stops, patients rapidly lose hair once more. It's our hope that REZPEG may offer a fresh treatment approach and a durable answer for those fighting this chronic illness; when it comes to type 1 diabetes, REZPEG holds substantial promise as a T regulatory cell therapy capable of slowing the worsening loss of insulin-producing beta cells, which are what the patient's hyperactive immune cells attack in this disease. We look forward to launching later this year the crucial proof of concept trial in new-onset type 1 diabetes, which TrialNet is sponsoring and funding. Last of all, regarding our early-stage immunology pipeline and REZPEG, we're moving NKTR-0165, our TNFR2 agonist antibody program, ahead through IND-enabling studies during this year, and our progress on this front has been excellent. We expect to finish these studies in 2025 and will be ready to make an IND filing. Moreover, the bispecific program, NKTR-0166, which combines a TNFR2 epitope with a validated antibody target, remains on track too, and we're pushing this new program forward into preclinical studies. In closing, our financial position stays solid, with a runway extending into the fourth quarter of 2026. Having said that, I'll pass the call to JZ for a look at the upcoming data milestones. JZ?

Jonathan Zalevsky

executive
#3

Thank you, Howard, and I appreciate everyone joining the call today. Let me start by walking you through some specifics of how our REZPEG trials are structured, since these studies are going to give Nektar a number of data catalysts across the coming nine months. Starting with atopic dermatitis: RESOLVE-AD brought in roughly 400 patients who had not previously received biologics, enrolling them between October 2023 and January 2025, drawn from several regions around the world. This 52-week trial has two separate parts: induction and maintenance. You may remember that the earlier REZPEG phase 1b trial contained only the induction portion, consisting of 12 weeks of therapy. What we're aiming for in this phase 2b trial is to pin down an appropriate dose for a first 16-week induction window — one that could become our phase three dose — and likewise to determine a maintenance dosing schedule to be administered for another 36 weeks following induction, so that patients either hold onto or perhaps gain even more benefit. During induction, we're comparing three dosing schedules against placebo, using a 3:3:3:2 allocation: a high dose arm at 24 micrograms per kilogram administered twice a month, a middle dose arm at 18 micrograms per kilogram administered twice a month, and a lower-exposure arm at 24 micrograms per kilogram administered once a month — all with the aim, as I mentioned, of settling on an induction dose to take forward into phase three. As you may recall, the 24 microgram per kilogram dose administered every two weeks came from the phase 1b trial of rezpegaldesleukin in atopic dermatitis; after just a 12-week induction course in that trial, that arm demonstrated statistical significance versus placebo. REZPEG produced an 83% reduction in EASI scores, versus 47% for placebo. Once treatment was halted in phase 1b, we saw a robust remissive signal, with patients holding their lowered EASI scores across 36 weeks after the 24 microgram per kilogram twice-a-month dose ceased at week 12. The middle dose, 18 micrograms per kilogram administered twice a month, sits between the 12 microgram per kilogram strength examined in phase 1b and the top dose studied, 24. And lastly, so that we could get close to matching the PK exposure of the 12 microgram per kilogram low dose from phase 1b, we also administered 24 micrograms per kilogram once a month. Importantly, since REZPEG acts as an agonist, we kept weight-based dosing in both our phase 2b atopic dermatitis trial and the alopecia trial. Our primary endpoint is the mean change from baseline in EASI score, and we're additionally assessing secondary endpoints including EASI75, EASI90, BSA, ITCH, and VIGA scores. As you'll remember, every patient in the phase 1b REZPEG atopic dermatitis trial was enrolled in the U.S. That's because we saw a larger placebo effect in the U.S. In our phase 1b trial, both we and other researchers ran into the same problem, so for the phase 2b trial we aimed for a smaller number of participants here in America. Consequently, just 17% of the people enrolled were in the U.S., while 67% were in Europe — mostly Poland — and the rest came from Australia and Canada. We also adopted several other significant steps to tackle the elevated placebo rates seen in prior atopic dermatitis trials. To begin with, ahead of randomization in RESOLVE-AD, we gathered baseline scores from patients both at screening and once more at randomization. Any patient whose baseline EASI scores fluctuated widely was failed at screening; this step was taken so that individuals with unstable disease would be excluded. A further central aim for the phase 2b trial involved relying mainly on locations overseen by board-certified dermatologists possessing particular background in atopic dermatitis trials that had succeeded. That way, we made certain that higher-quality locations took part in the trial. Enrollment spanned 110 sites worldwide, all selected with care and given training through our study operations. As I mentioned before, a robust signal of remissive effect emerged following the 12-week induction phase in our phase 1b, even once two twice-monthly dose regimens had been removed after week 12. For phase 2b, we are investigating how continued dosing with rezpegaldesleukin will appear following the induction phase, over a maintenance window of 36 weeks. Once the 16-week induction phase ended, those patients who reached an EASI 50 score or better were re-randomized into one of two maintenance regimens at the same dose level they started on, for a 36-week treatment span, given either once a month or once every three months. We look forward to observing what happens when treatment with rezpegaldesleukin continues past induction — which, as Howard Robin noted previously, will produce a future data readout in early 2026. Any patient failing to hit an EASI 50 or superior efficacy threshold by week 16 could enter an escape arm, consisting of the 24 microgram per kilogram dose administered every two weeks. Since rezpegaldesleukin works through an immune modulating mechanism, we are additionally tracking participants for one year following the end of the 52-week treatment period, which lets us assess rezpegaldesleukin's potential to deliver a long-term remissive effect in patients. Our goal is to grasp how rezpegaldesleukin sets itself apart from IL-13-based mechanisms and JAK inhibitors, in which disease returns for a substantial share of patients once treatment stops. Now, turning to alopecia areata, as Howard mentioned, we anticipate top-line results from the 90-patient alopecia trial in December of this year; that trial began in March of 2024, and we finished enrollment in February of this year at 30 sites worldwide. 62% of patients came from Poland, 24% from Canada, and the remainder from the U.S. The trial includes a 36-week treatment period and follows a design comparable to the phase 2 study of baricitinib in alopecia. Alopecia areata is a skin condition where the immune system of the patient mistakenly targets the hair follicle, interfering with the body's usual capacity to retain and produce hair, which results in significant hair shedding and an inability to regrow hair. A strong scientific basis exists for using rezpegaldesleukin in this indication, grounded in how Tregs can either stop or reduce the disease's underlying pathology. To qualify for enrollment, patients needed to show severe to very severe disease, which was defined as a Severity of Alopecia Tool score, or SALT, of 50 to 100 lasting a minimum of six months. Two dose levels are being assessed by us: 24 micrograms per kilogram and 18 micrograms per kilogram, administered once every two weeks, against placebo. In this disease setting, placebo rates are usually fairly low, coming in under 10%. Mean percent improvement in SALT at week 36 serves as our primary endpoint for this study. Additionally, we plan to examine a variety of other secondary endpoints, such as the share of patients achieving specific degrees of improvement in their SALT score, which includes the regulatory approval endpoint for a phase three study, the SALT 20 responder analysis. As Howard mentioned, we are also enthusiastic about the launch of the PHASE II TrialNet-sponsored trial in type 1 diabetes for rezpegaldesleukin.

Jonathan Zalevsky

executive
#4

This placebo-controlled trial, which involves 66 patients, is going to include individuals with stage three newly diagnosed type 1 diabetes, and we're eager to make the rezpegaldesleukin drug available for this significant indication. Lastly, our IND enabling work for NKTR-0165, a novel TNFR2 agonist antibody program, is advancing nicely. Agonism at TNFR2 boosts Treg activity and helps preserve Treg lineage stability, particularly within the non-lymphatic tissue compartment. Preclinical results from this effort, which were shared at EULAR last year, showed that NKTR-0165 is highly specific in signaling via TNFR2 on Tregs and in augmenting their immunoregulatory phenotype. It further indicated that the agonist we found can signal through the TNFR2 multimeric receptor as a single-arm monovalent antibody. In our view, this is the sole antibody within this class under development that possesses this characteristic. We're thrilled about the distinct, differentiated profile of this antibody, and we think it could turn into a first-in-class therapy for a range of autoimmune conditions, such as multiple sclerosis, ulcerative colitis, and vitiligo. Additionally, we're putting together a pipeline of bispecific molecules that combine TNFR2 agonism with other antibody targets, and we've pinpointed the initial bispecific antibody, NKTR-0166, within this program. This inaugural bispecific antibody merges a TNFR2 epitope with another validated antibody target, and we're kicking off our preclinical studies at this time. We're eager to share further information about this antibody as the studies move forward. Regarding NKTR-255, our IL-15-based oncology program, I'm delighted to report that data from our partners at the Fred Hutchinson Cancer Center in Seattle got accepted for an oral presentation at this year's European Hematology Association Conference, which is taking place in Milan. This marks the initial data to be presented from their investigator-sponsored trial of NKTR-255 after CD19-directed CAR T cells BRIANZI in patients with second and third-line large B-cell lymphoma. We think these findings bolster the potential for NKTR-255 to enhance existing cell therapies for patients. We're continuing to look into ways to keep developing this drug candidate alongside collaborators; at this point, I'd like to hand the call over to Sandy for a rundown of our financials.

Sandra Gardiner

executive
#5

Thanks, JZ, and good afternoon to all of you. As of the close of the first quarter of 2025, we held $220.7 million in cash and investments, and our balance sheet carries no debt whatsoever. Our financial position remains solid, and we continue to anticipate that our cash runway will last into the fourth quarter of 2026, with roughly $100 million in cash and investments on hand at the end of 2025. Now, looking at the income statement: revenue for the first quarter of 2025 came in at $10.5 million, which fell within our guidance range and consisted entirely of non-cash royalty revenue. For the rest of 2025, we presently expect quarterly revenue to stay at a level comparable to Q1, which adds up to approximately $40 million across the full year. R&D expenses for the first quarter of 2025 were $30.5 million, and we continue to project full-year R&D expense in the range of $110 million to $120 million, which includes $5 million to $10 million in non-cash depreciation and stock-based compensation expense. Our G&A expenses for the first quarter were $24.3 million. For the full year of 2025, we still expect G&A expense to land between $60 million and $65 million, which includes $5million to $10 million in non-cash depreciation and stock-based compensation expense. Keep in mind that our operating expenses do not occur evenly across the year and will shift depending on the volume and nature of activities in any given quarter; as an example, R&D expenses run higher during the first half of the year because of increased study operational activities in our RESOLVE-AD PHASE II atopic dermatitis study. Non-cash interest expense for the first quarter was $5 million, and we expect it to stay at a comparable level across the remaining three quarters, amounting to approximately $20 million for 2025; in this quarter, we added a new non-operating line item to our income statement called Gain or Loss from Equity Method Investment. As a reminder, on December 2, 2024, we closed the sale of our Huntsville manufacturing facility for consideration of $64.7 million in cash, net of transaction costs, plus approximately 20% ownership in the new portfolio company, Gannett Biochem, or Gannett. As required under the equity method of accounting, our investment in Gannett was recorded at fair value. At the end of each subsequent period, our share of Gannett's gains or losses is recorded through the hypothetical liquidation at book value, or HLBV, method. The HLBV method determines the change in the hypothetical amount we would be entitled to receive if Gannett were liquidated at book value at the close of each period. This is a non-cash charge that is recorded outside of Nektar's operating expenses and may swing from a loss to a gain from one period to the next. In the first quarter, as a result of this accounting methodology, we recorded a non-cash loss from equity method investment of $4.5 million, and we currently anticipate a loss of approximately $10 million for the full year 2025. Importantly, as I just mentioned, this is non-cash; we have no commitments to contribute cash to Gannett as an equity investor. We're just offering this as some administrative details, so you're able to project what remains of 2025 regarding this new non-cash line item. For the first quarter, our net loss came to $50.9 million, which works out to $0.24 basic and diluted net loss per share. The net loss prior to the equity method investment was $46.4 million, which equates to a non-GAAP basic and diluted net loss per share of $0.22. As I mentioned before, we continue to anticipate finishing the year with roughly $100 million in cash and investments, and our cash runway reaches into the fourth quarter of 2026. Last, as we approach our June data reporting, we plan to go into a quiet period throughout the month of June, until we report the top-line results for the RESPEG atopic dermatitis study. With that, we'll now open the call for questions. Operator?

Dominic Risso-Gill

executive
#6

Hello, Dominic On speaking on behalf of Yaz. We appreciate you answering what we've asked, and congratulations on the quarter. There are two things I'd like to ask. First, would you mind reminding everyone what results you're looking for in Resolve AD before it can advance to a phase three trial? Do you intend to proceed using either 1 or 2 doses for that study? And what level of placebo response are you anticipating in Resolve AD? Thanks.

Howard W Robin

executive
#7

JZ, would you like to answer that?

Jonathan Zalevsky

executive
#8

Absolutely, and thanks for asking. To start with, one goal for us is this: we already possess phase one results, and proof of concept in atopic dermatitis has been shown by us. Replicating those results is something we want to observe; that stands as one element of efficacy we hope to see. Beyond that, we would put the findings side by side with other major comparators. A highly significant comparator is Dupixent; within this area it represents the top standard of care; at a minimum, we want to land within the efficacy range that Dupixent demonstrates; going even further and beating that, plus reproducing what we found in phase one, is what we would like. Regarding how many dose levels we hope to examine, the aim behind the phase 2b trial is that it functions as a typical dose range finding study. In the best situation, a fairly obvious dose along with a dose regimen would be pinpointed by us to carry onward. Naturally, whatever the results reveal would have to be seen by us, yet under ideal circumstances, a single dose level would be the one we advance into the phase 3 studies. Could you please remind me what your third question was?

Dominic Risso-Gill

executive
#9

Yeah. It was, what are the expectations for the placebo response in Resolve-AD? Yeah. Okay. Thank you. As I mentioned in the call, in the phase 1, we used sites that were 100% in the 13 sites.

Jonathan Zalevsky

executive
#10

We observed a placebo response of roughly 47%, which came in somewhat elevated, though it remains within what modern trials typically show — just toward the upper boundary. That certainly mirrors a broader pattern we're noticing, especially at sites located in the U.S. So we acted proactively to try to keep that placebo response rate in check: we enrolled only a portion of patients in the U.S., 17%, and brought in the remainder of the patient population from the rest of the world, plus some other steps I mentioned, like relying on board-certified dermatologists at most sites so that disease ratings stay consistent and of the highest quality. We'd prefer to see a rate lower than, say, the one from phase 1b. We look forward to sharing the actual placebo response rate when we prepare and report top line next month.

Julian Harrison

analyst
#11

Hello there. Nice work on the advances, and I appreciate your time for my questions; regarding the phase 2b atopic derm data that should arrive in June, or more precisely the trial itself, I have one particular thing to ask. Could you let us know what number of patients have moved into the maintenance part of the study up to now, and among them, what number have switched over into the escape arm of the study? Is that information blinded to you, or is it possibly something you're in a position to share at this point? JZ, were you able to hear that question?

Jonathan Zalevsky

executive
#12

Julian. Yes. This is JZ speaking. Yeah. That's a fair question. That type of information isn't something we can share at this point, but we'll be sharing it, along with additional details about the data and the real results, next month, when we present the study's top-line results. All right.

Julian Harrison

analyst
#13

Thank you.

Jay Olson

analyst
#14

Oh, hi there. Nice work on the advancement, and I appreciate you fielding our questions. At the point when you disclose the findings from the phase 2b results study, could you discuss the extent of the information you intend to reveal and, among the secondary endpoints, which matter the most?

Jonathan Zalevsky

executive
#15

Yes. Thank you, Jay; so something that's somewhat distinctive regarding dermatology conferences is that they tend to be a bit more permissive than, for instance, ASCO regarding embargoed data. I believe that's beneficial in this case. Of course, at the time we unveil the top-line data, the primary endpoint is going to be a crucial component we'd unveil, and that is the % change from baseline in EASI score; and relative to placebo, every cohort individually. There are secondary endpoints, and you inquired about which ones matter quite a bit. Certainly EASI-75, EASI-90, VIGA matter quite a bit. Likely ITCH matters quite a bit too. I mean, those are the ones that really, first of all, serve as registrating endpoints in the instance of EASI-75 and VIGA. Also, items such as ITCH are simply essential for the sorts of comparisons we perform; we would also provide the picture. The picture isn't merely efficacy. It would be the overall tolerability, the overall capacity to grasp both risk and the benefit of the drug. I hope that offers you a sense of the sorts of things we would unveil.

Jay Olson

analyst
#16

Yes, definitely. That's really useful. If I may, I'd like to ask a follow-up question. For phase three, will you use dosing based on weight, or will it be a fixed dose?

Jonathan Zalevsky

executive
#17

Yes. Something we've come to understand regarding this drug as an agonist is that precise dosing matters a great deal. What we've determined is essential is dosing by weight. We intend to keep dosing based on weight. This approach is fairly standard. A large number of drugs are given according to what are known as weight bands. When someone falls between weight A and weight B, they receive this SKU — or not SKU — for instance, Orencia and other medications. Quite a few other drugs are administered that way. We would be employing weight-based dosing. Another aim over the long term would be for us to introduce an auto injector while preserving that sort of weight-based banding as our dosing strategy.

Jay Olson

analyst
#18

Great. Thanks so much for taking the question.

Roger Song

analyst
#19

Great. Thanks for the update and taking our question. Could you remind us of the dropout rate in your phase 1b atopic dermatitis trial? I realize the N is small. What should we expect for your phase 2? Is there anything you can share in a blinded manner? What discontinuation are you observing? Would you report both ITT and ESTAMON for the efficacy endpoint?

Jonathan Zalevsky

executive
#20

Yeah. Hey, Roger. Yeah. Thanks for the question. Last year, when the phase 1b results were published in our Nature Communications paper, we reported discontinuation rates of 20% to 30% across the placebo group and the two REZPEG dose levels. Placebo actually had the higher figure at 30%, while the REZPEG arms—both low dose and high dose—landed in the low to mid-20% range. That information was shared. Take a study such as the lebrikizumab phase 2 trial, for instance: in their overall pooled analysis, they showed a dropout rate of roughly 28%, I believe—just one more point of comparison. When it comes to June, we'll be sharing the dropout figures. For instance, we'll cover those who stopped treatment while in the induction phase, plus—as was asked earlier—those who finished induction and then either moved into maintenance through re-randomization or entered the escape arm. Keep an eye out; all those findings will come your way next month.

Roger Song

analyst
#21

Understood. Now, regarding what comes next — since the PHASE II trial involved a biologic non-upatient population, how do you think about broadening this to post-biologics and afterward into the phase three? Thank you.

Jonathan Zalevsky

executive
#22

Yes. Everything we have is truly founded on the results from our own proof of concept study, correct? That is the reason we conducted that phase one trial in biologic naive patients, and we conducted the PHASE II in biologic naive patients. We would anticipate conducting our phase three studies in the biologic naive patients as well. That said, as part of the phase three program, we would additionally examine the drug in biologic experienced patients; that is something we would carry out within the phase three program. Approaches differ from one company to another. To illustrate, Amgen, through their ROCA program, merged biologic naive and experienced patients into a single study, while lebrikizumab and amytlamab conducted distinct studies for those populations. We have yet to determine which approach suits us best, but within the phase three program we will certainly assess both the naive and the experienced patient populations.

Roger Song

analyst
#23

Roger, thanks — and this will be our final quick one. Regarding the partnership side of things, would you look to bring in a partner once PHASE II wraps up, or does REZPEG move into phase three under Nektar alone? Appreciate it. Jonathan, over to you.

Jonathan Zalevsky

executive
#24

Yes, and thanks for raising that, Roger — it's a strong question. Here's how I'd frame it: when you examine where Nektar sits financially right now, it's obvious we can't run an entire phase three effort by ourselves without someone alongside us. So what we intend to do is evaluate how strong and how high-quality the data looks, and we'll be speaking with companies about working together. To be clear, that isn't the same as outlicensing the drug — there's no chance of that happening. Our conversations with companies will aim at structuring a collaboration that keeps dilution of our investors' financing to a minimum, while at the same time letting us hold onto a meaningful share of ownership in the drug. You can achieve that through many different structures, but the direction we're most likely to take is plainly a collaboration.

Roger Song

analyst
#25

Great, that's all we had.

Mayank Mamtani

analyst
#26

Hello, and thanks for fielding our questions. JZ, could you share any insight into what your baseline EASI might be, and how significant is the shift from 12 to 16 weeks in this phase 2b compared with phase 1b when it comes to distinguishing from placebo? Do you anticipate that every dose level — including the 24 mg/day given once monthly — will essentially achieve statistical significance, with the monthly dose representing the lowest therapeutically effective dose?

Jonathan Zalevsky

executive
#27

Okay, so thank you, Mayank. When we share the top-line data, naturally we'll provide the full baseline EASI details. What I can say is that given the types of forward-looking choices we made in designing the trial — things like the geographic distribution, plus concentrating on seasoned dermatologists, board-certified derms who have a track record of successful study participation — our hope is to see a baseline EASI score falling somewhere in the 25 to 30 range. In our view, when you examine studies that have succeeded, whether those are PHASE II or phase three, that range represents a strong place to land. As you're aware, based on what we've published, our phase one figure came in somewhat below that. We landed in the 22 to 23 bracket. Again, those were entirely U.S. sites; for this study, we'd prefer to see a baseline EASI that's higher. You raised another fascinating point regarding what happens when you extend the dosing duration, the total interval between doses; we believe that matters a great deal. The phase 1b gave us really valuable information, demonstrating that a 12-week regimen dosed twice per month was absolutely capable of producing substantial efficacy, and it could bring about a remissive response. That showed up in most participants, yet it also became clear that certain individuals might have achieved more with extra dosing. Looking at that period from week 12 to week 19 when no drug was given, we saw a handful of patients across the various dose levels lose a response that had genuinely been meaningful, and afterward that response diminished. Plainly, there were patients who would have benefited from further dosing. Among the first things we intend to examine in this trial is extending the induction phase from 12 to 16 weeks. That additionally provides more room, as you put it, for separation from placebo. And then, past that, there's the reality that we continue dosing throughout the maintenance phase, which is something else I noted we're quite enthusiastic about, since it's conceivable we haven't yet fully characterized how much efficacy is achievable. With ongoing treatment across 52 weeks, patients might experience still greater improvements; we're eager to observe what that extra dosing produces. Regarding your final question on the various dose levels, we offered more detail on today's call concerning our expectations for PK exposure and the sort of AUC that aligns across those levels. And don't forget, this trial is extremely well-powered. We brought 400 patients into the study so we could populate the maintenance arms. What that buys us is a very well-powered induction, which hands us an excellent opportunity and a strong likelihood of achieving significance across several dose arms. Appreciate the questions, Mayank.

Mayank Mamtani

analyst
#28

Thank you. I'd like to fit in one question about the alopecia study, if that's all right. Do you have any idea what share of patients fall into the very severe versus the severe subgroup? And if you could say something about how the response unfolds over time compared with the fairly rapid onset you see in AD, what would you anticipate for those kinetics? I have just one more follow-up after this.

Jonathan Zalevsky

executive
#29

Okay, then. When you examine the epidemiology alone, and consider those with a SALT score of 50 or above, what you'd discover is that somewhere between one-third and one-half fall into the very severe group — meaning 95 and higher, correct? Those individuals are likewise the ones who typically end up as candidates for clinical trials too. That's simply the point where the epidemiology breaks down, in that from one-third to one-half sit within that very severe category, defined as 95 to 100 on the SALT score. Regarding your other question about onset, that's a really fascinating one. The physiology behind that disease differs greatly; with atopic dermatitis, what you're essentially dealing with is an organ in the skin that bounces back fast. As you're aware, rashes may show up, appear, and resolve quickly. The same goes for other excoriation, lichenification, and additional features of the disease. Hair operates by its own rules, doesn't it? Hair growth has distinct stages; for alopecia patients, there's an arrest of the hair follicle. Inflammation is present that slows things down, and it truly disrupts the stem cell, a portion of the disease. That's the reason we're actually running a 36-week induction period in that study. What we observe is that even with JAK inhibitors, right, growing hair can take time. We're conducting a longer induction period; in December, we look forward to presenting the top-line results of that study. At that point we'll be able to characterize not only the magnitude, but the kinetics of the response as well; stay tuned until December for that.

Mayank Mamtani

analyst
#30

Okay, so this is from Cartwright. Is there anything you can share regarding the Lilly lawsuit, perhaps an update on what happens next, and whether REZPEG moving into late-stage development could affect any potential damages? Thanks once more for taking our question.

Jonathan Zalevsky

executive
#31

Well, I clearly can't get into specifics about the lawsuit. What I can say is that we firmly feel Lilly has harmed us. We are definitely taking a forceful approach with this case. In my view, regardless of whether REZPEG wins or REZPEG loses, I don't believe that really changes much about the harm they've caused us. Let's keep watching and waiting as we head toward a trial.

Mayank Mamtani

analyst
#32

Got it. Thanks very much.

Arthur He

analyst
#33

Hi there, good afternoon. How are things with you and the team? Appreciate you fielding my question. JZ, you anticipated exactly what I was going to ask regarding sharing the dose level for the AA study. I'm curious, if this phase 2b kicking off in the AA winds up hitting the expectations you folks have, what should our thinking be around the design when you're assessing maintenance in the AA patient population? Would it take a design path comparable to the AD study?

Jonathan Zalevsky

executive
#34

Yes; that's a terrific question, Arthur. Yes. Appreciate it. Something we will discover in this phase 2b study is the outcome once we halt treatment, correct? Within the study design, there is a nine-month induction followed by a six-month off-treatment period. What we hoped and wanted when designing the study that way was to observe the same sort of remissive potential in alopecia that we observed in atopic dermatitis during that off-drug period there. That would amount to a completely transformational change in this indication. To start with, no biologic has approval in this disease. The JAK inhibitors can work for people with alopecia. These treatments can be tough on people, because with this condition you have to stay on them for a very long period, and on top of that, the dose needs to be increased for patients. Howard and I like to describe it this way: it's really challenging for those patients, since the moment you discontinue the JAK inhibitor, hair shedding happens rapidly, and there's no regrowth and nothing preserved of what had grown back. We believe there's an opportunity here that is genuinely one of a kind. Once more, the prospect of occupying a highly, highly promising spot as a biologic under investigation, plus the chance to be involved so early on in this area as a biologic therapy. When it comes to designing a phase three trial, the first thing we'd need is the phase two data, correct? We would need to understand the dose-ranging work completed during that phase two study. When examining the off-drug period, we'd consider which maintenance regimen makes the most sense. In all likelihood, our strategy for treating alopecia would mirror our strategy for atopic dermatitis — beginning with an induction phase involving more frequent dosing, followed by a maintenance phase with far less frequent dosing. That's probably how it would look. Naturally, before we can lock in that ultimate design, we'll need to review the study's completed findings.

Arthur He

analyst
#35

Thanks, JZ. I just have one quick question about how the alopecia trial was designed from a technical standpoint. I saw that patients who didn't get their SALT score below 20 are able to receive another 16 weeks of treatment, correct? Those same patients would then be monitored for another 24 weeks. Is that accurate? What I'm getting at is that, for them, the overall duration of the study would end up being somewhat longer.

Jonathan Zalevsky

executive
#36

The second one is right; in those cases, all participants receive 24 weeks with no drug. Even if certain individuals were still improving when week 36 ended and had an extension, they would nonetheless be tracked for 24 weeks once dosing stopped. That's correct.

Arthur He

analyst
#37

Okay, understood. Yes, I appreciate you answering my question.

Jessica Fye

analyst
#38

Hi, everyone. Good afternoon, and thank you for fielding my question. Should we reasonably anticipate that you'd hold off until the 36-week AD data is available before you go after an end-of-PHASE II meeting with FDA and get ready to launch a phase three trial? Or might there be some inclination to sit down with the FDA earlier, on the strength of this data that's coming up, and get phase three underway that much faster? Thank you.

Jonathan Zalevsky

executive
#39

Yes. I appreciate that question, Jess. It's the second one. We don't need to hold off for the maintenance portion to finish, which would arrive in the early part of next year, before we engage with the FDA regarding the induction regimen. As a matter of fact, our plan is that using the top-line data arriving next month, we'd start looking toward an end-of-PHASE II meeting, with the 16-week induction data serving as the primary substance and substrate, along with the driver for the phase three study design that we'd advance. Yes, in fact, waiting isn't necessary for us. What we aim for is really to sustain the program's momentum. Should the study deliver the sort of results we believe it can, we'd intend to act fast, preserve that momentum, and look toward phase three, entering that phase three program as rapidly as possible.

Jessica Fye

analyst
#40

Great, thank you.

Andy Hsieh

analyst
#41

Thanks for taking our questions. I have two. First, I'm curious about the atopic dermatitis protocol — are patients permitted to stop taking the drug while remaining enrolled in the trial? The reason I ask is that perhaps at the first look, you could potentially get a glimpse into a potential remissive effect, as you mentioned, JZ, for those patients who are off-drug but still on trial. So that's question number one. Question number two is about the primary endpoint — I'm curious which imputation method you're using. I think this goes back to Roger's question before, but I have the same question. Thank you.

Jonathan Zalevsky

executive
#42

Alright, absolutely. Regarding what you asked first — just as with any trial, there are criteria that determine when someone halts participation or discontinues the medication, correct? Should a patient meet those criteria, the same as in any other trial, they remain enrolled. Follow-up appointments keep happening — not merely a final visit at study close, but even following the conclusion of treatment, monitoring can carry on. Our trial operates identically to every other one, and it permits that arrangement. Yes, that's something our trial allows. Your next question concerned imputation. The approaches to imputation being applied are the standard ones you'd see in PHASE II research, correct? When you're reporting data like this, the FDA prefers that you work with an estimate-based method. Intercurrent events are a category of events that are clearly defined. For any trial at the size of a PHASE II study, the FDA provides this guidance to every sponsor: we would rely on a primary estimate analysis. Once again, this involves the usual imputation techniques that you'd find in other studies. As we share the findings, we'll go deeper into the methodology details, so that information reaches you ahead of the protocol—for instance, at the point we publish the study results. Hopefully that conveys the general sense. It's a standard imputation paired with a primary estimate analysis.

Andy Hsieh

analyst
#43

All right, that's useful. Thanks, JZ.

Howard W Robin

executive
#44

Thanks to everyone for being with us today. Your ongoing backing means a great deal to us. I'd like to express appreciation to each of our team members for the effort and care they put in. I'm eager to present our REZPEG data in June. Keep watching for that.

Operator

operator
#45

Thanks a lot; that wraps up the conference call for today. We appreciate you joining us. You're welcome to disconnect at this point. Have a great day, everybody.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.